Defining the Optimal Treatment Strategy for Localized Prostate Cancer Patients: A Survey of Ongoing Studies at the National Cancer Institute of Canada Clinical Trials Group

  • Wendy R. Parulekar NCIC CTG
  • Michael McKenzie BCCA Vancouver
  • Kim N Chi BCCA Vancouver
  • Laurence Klotz Sunnybrook Health Sciences Centre Toronto
  • Charles Catton Princess Margaret Hospital Toronto
  • Michael Brundage Cancer Centre of Southeastern ON at Kingston General Hospital
  • Keyue Ding NCIC Clinical Trials Group
  • Andrea Hiltz NCIC Clinical Trials Group
  • Ralph Meyer NCIC Clinical Trials Group
  • Fred Saad CHUM - Hopital Notre Dame Montreal

Abstract

The designation ‘clinically localized prostate cancer’ comprises a group of biologically heterogeneous tumours with different growth rates and risks of relapse. Since prostate cancer is primarily a disease of older men, treatment selection must take into account the prognosis of the tumour, patient age, comorbidities, side effects of treatment and patient preferences. Clinical trials must identify the different prognostic groups and test the appropriate treatment strategies within these subgroups.
How to Cite
Parulekar, W. R., McKenzie, M., Chi, K. N., Klotz, L., Catton, C., Brundage, M., Ding, K., Hiltz, A., Meyer, R., & Saad, F. (1). Defining the Optimal Treatment Strategy for Localized Prostate Cancer Patients: A Survey of Ongoing Studies at the National Cancer Institute of Canada Clinical Trials Group. Current Oncology, 15(4), 14-19. https://doi.org/10.3747/co.v15i4.257
Section
Canadian Centre Activities